EyePoint Pharmaceuticals’ Yutiq for Posterior Segment Uveitis to be Presented at the 2018 ARVO Annual Meeting

EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting being held in Honolulu, Hawaii, from April 29 – May 3, 2018.

• The abstract accepted for a paper presentation is titled “Safety and Efficacy of an intravitreal 0.18 mg fluocinolone acetonide insert (FAi) for the treatment of non-infectious posterior segment uveitis (NIPU) – pooled results of two phase 3 trials”. The data will be presented by Eric Suhler, M.D., Casey Eye Institute-OHSU and VA Portland HCS, Portland, Oregon, during the session titled: “Advances in Clinical Therapeutics for Uveitis” on Thursday, May 3, 2018, from 12:00 p.m. to 12:15 p.m. HST.
• The abstract accepted for a poster presentation is titled “Controlling Posterior Segment Uveitic Recurrences: Results from a Phase 3 Study of 0.18 mg fluocinolone acetonide insert (FAi) in subjects with chronic non-infectious uveitis affecting the posterior segment”. The data will be presented by Quan Nguyen, M.D., Byers Eye Institute, Stanford University, Palo Alto, California, during the session titled “Uveitis and Scleritis: Therapeutics” on Sunday, April 29, 2018, from 1:00 p.m. to 2:45 p.m. HST.

“ARVO is one of the most important ophthalmology conferences of the year and we are extremely pleased that data from our Yutiq phase 3 studies has been selected for presentations at ARVO and we look forward to sharing the data with retinal and uveitis specialists,” commented Nancy Lurker, President and Chief Executive Officer. “Our NDA for Yutiq for the treatment of noninfectious posterior segment uveitis is currently under review by the FDA with a PDUFA date of November 5, 2018. We believe that, if approved, Yutiq has the potential to become an important new treatment option for the thousands of patients suffering from this disease, which is the third leading cause of blindness.”